First Light Asset Management LLC Has $27.21 Million Stake in Harvard Bioscience, Inc. (HBIO)
First Light Asset Management LLC lifted its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 17.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,441,290 shares of the medical instruments supplier’s stock after purchasing an additional 802,639 shares during the quarter. Harvard Bioscience accounts for approximately 6.0% of First Light Asset Management LLC’s holdings, making the stock its 4th largest position. First Light Asset Management LLC owned approximately 15.12% of Harvard Bioscience worth $27,206,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in HBIO. Element Capital Management LLC bought a new position in Harvard Bioscience during the first quarter valued at about $130,000. C M Bidwell & Associates Ltd. bought a new position in Harvard Bioscience during the first quarter valued at about $133,000. Russell Investments Group Ltd. boosted its stake in Harvard Bioscience by 41.7% during the first quarter. Russell Investments Group Ltd. now owns 37,058 shares of the medical instruments supplier’s stock valued at $186,000 after buying an additional 10,900 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Harvard Bioscience by 5.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,867,135 shares of the medical instruments supplier’s stock valued at $9,336,000 after buying an additional 101,965 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan bought a new position in Harvard Bioscience during the first quarter valued at about $393,000. 64.59% of the stock is owned by institutional investors.
Harvard Bioscience opened at $5.25 on Thursday, MarketBeat reports. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.50 and a quick ratio of 1.25. Harvard Bioscience, Inc. has a 1-year low of $2.35 and a 1-year high of $6.15. The firm has a market capitalization of $188.90 million, a P/E ratio of 105.00 and a beta of 1.21.
Several research analysts recently weighed in on HBIO shares. Benchmark set a $10.00 target price on Harvard Bioscience and gave the company a “buy” rating in a research note on Monday, April 16th. ValuEngine raised Harvard Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Zacks Investment Research cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. One equities research analyst has rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.75.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.